Product theaters will again be held this year during the annual meeting. These promotional programs are being held as an extension of the Exhibit Hall. They feature promotional programs supported by exhibitors. CME credit is not provided for these sessions. The 60-minute sessions will be held in Exhibit Hall A-C on the Exhibit Level in the Moscone Convention Center. Sessions will run from Sunday, May 19, to Tuesday, May 21, with three sessions each day at 11 a.m. and 1 p.m. Boxed lunches and beverages are provided by APA for the programs. Topics may include treatment management, disease updates, and issues of interest to the supporting company. Supporters of the sessions include Takeda Pharmaceuticals America Inc., Lundbeck Inc., Sunovion Pharmaceuticals Inc., Genentech Inc., Genomind, AstraZeneca, and Otsuka America Pharmaceuticals Inc. Look for signs announcing the presenters and topics in the convention center and outside the product theater.
All product theaters will be held in Booth 2326 in Exhibit Hall A-C, in the Moscone Convention Center. Seating is limited to 250 on a first-come basis.
SUNDAY, MAY 19
11 a.m.-NoonSponsored by Takeda Pharmaceuticals America Inc. and Lundbeck Inc. Depression: Deeper Evaluation of Symptoms and NeurobiologyPresenter: Pierre Blier, M.D., Ph.D., director of the Mood Disorders Research Unit University of Ottawa Institute of Mental Health Research and professor in the departments of Psychiatry and Cellular and Molecular Medicine, University of Ottawa
1 p.m.-2 p.m.Sponsored by Sunovion Pharmaceuticals Inc.Challenges and Opportunities in Schizophrenia Treatment Presenter: Stephen M. Stahl, M.D., Ph.D., adjunct professor of psychiatry, University of California San Diego School of Medicine; honorary visiting senior fellow, University of Cambridge, United Kingdom; editor-in-chief, CNS Spectrums; director of Psychopharmacology Services, California Department of State Hospitals
MONDAY, MAY 20
11 a.m. -NoonSponsored by Genentech Inc.Novel Mechanisms and Disease Awareness (NMDA) in SchizophreniaPresenter: Peter J. Weiden, M.D., professor of psychiatry and director, Department of Psychiatry Psychosis Treatment Program, University of Illinois at Chicago
1 p.m.-2 p.m.Supported by GenomindThe Link Between Mental and Physical Health: Using Genetics to Treat the Whole Patient Presenter: Jay Lombard, D.O., cofounder, chief scientific officer, and medical director for Genomind
TUESDAY, MAY 21
11 a.m.-NoonSupported by AstraZenecaAn Approach to Treating Acute Depressive Episodes of Bipolar DisorderPresenter: Richard Jackson, M.D., associate clinical professor of psychiatry, Wayne State University School of Medicine; assistant clinical adjunct professor of psychiatry, University of Michigan School of Medicine
1 p.m.-2 p.m.Sponsored by Otsuka America Pharmaceutical Inc. and Lundbeck Inc.Help Protect Your Patients From Relapse: A New Treatment Option for Schizophrenia Presenter: Andrew J. Cutler, M.D., founder, Florida Clinical Research Center, and assistant professor of psychiatry, the University of Florida ■
